source
- FDA grants accelerated approval to Tudriqev viral therapy for PD-1-refractory advanced melanomaThe U.S. Food and Drug Administration has granted accelerated approval to Tudriqev (vusolimogene oderparepvec-wtpg), a genetically engineered oncolytic viral therapy for patients with advanced, tre…
- FDA selects Dexcom as first participant in TEMPO digital health pilotThe U.S. Food and Drug Administration announced that Dexcom, Inc. has been chosen as the inaugural manufacturer for the Technology-Enabled Meaningful Patient Outcomes (TEMPO) pilot focused on digit…